Pro: Factor Concentrates are Essential for Hemostasis in Complex Cardiac Surgery

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 32, Issue 1, 2018, Pages 558-564

  Ghadimi, Kamrouz ^a   Welsby, Ian J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

bleeding; cardiac surgery; coagulation; factor concentrates; hemostasis; prothrombin complex concentrates; transfusions

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; DABIGATRAN; EDOXABAN; FIBRINOGEN; FRESH FROZEN PLASMA; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; WARFARIN; BLOOD CLOTTING FACTOR 7A;

ATRIAL FIBRILLATION; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; EXTRACORPOREAL CIRCULATION; HEART SURGERY; HEMOPHILIA B; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; NOTE; OFF LABEL DRUG USE; PRIORITY JOURNAL; SURGICAL PATIENT; VENOUS THROMBOEMBOLISM; DRUG EFFECT;

ANTICOAGULANTS; BLOOD COAGULATION FACTORS; CARDIAC SURGICAL PROCEDURES; FACTOR VIIA; FIBRINOGEN; HEMOSTASIS; HUMANS;

EID: 85036648582     PISSN: 10530770     EISSN: 15328422     Source Type: Journal    
DOI: 10.1053/j.jvca.2017.05.042     Document Type: Note

References (41)

1. Ghadimi, K., Levy, J.H., Welsby, I.J., Perioperative management of the bleeding patient. Br J Anaesth 117 (2016), iii18–iii30.
2. Ghadimi, K., Levy, J.H., Welsby, I.J., Prothrombin complex concentrates for bleeding in the perioperative setting. Anesth Analg 122 (2016), 1287–1300.
3. Grottke, O., Levy, J.H., Prothrombin complex concentrates in trauma and perioperative bleeding. Anesthesiology 122 (2015), 923–931.
4. Levy, J.H., Tanaka, K.A., Dietrich, W., Perioperative hemostatic management of patients treated with vitamin K antagonists. Anesthesiology 109 (2008), 918–926.
5. Sarode, R., Milling, T.J. Jr, Refaai, M.A., et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: A randomized, plasma-controlled, phase IIIb study. Circulation 128 (2013), 1234–1243.
6. Sorensen, B., Spahn, D.R., Innerhofer, P., et al. Clinical review: Prothrombin complex concentrates—Evaluation of safety and thrombogenicity. Crit Care, 15, 2011, 201.
7. Key, N.S., Negrier, C., Coagulation factor concentrates: Past, present, and future. Lancet 370 (2007), 439–448.
8. Guest, J.F., Watson, H.G., Limaye, S., Modeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United Kingdom. Clin Ther 32 (2010), 2478–2493.
9. Vamvakas, E.C., Blajchman, M.A., Transfusion-related mortality: The ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 113 (2009), 3406–3417.
10. Muller, M.C., de Haan, R.J., Vroom, M.B., et al. Evaluation of a multi-center randomised clinical trial on prophylactic transfusion of fresh frozen plasma: Implications for future trials. Transfus Med 24 (2014), 292–296.
11. Raval, A.N., Cigarroa, J.E., Chung, M.K., et al. Management of patients on non-vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting: A scientific statement from the American Heart Association. Circulation 135 (2017), e604–e633.
12. Karkouti, K., Callum, J., Wijeysundera, D.N., et al. Point-of-care hemostatic testing in cardiac surgery: A stepped-wedge clustered randomized controlled trial. Circulation 134 (2016), 1152–1162.
13. Lohrmann, G.M., Atwal, D., Augoustides, J.G., et al. Reversal agents for the new generation of oral anticoagulants: Implications for the perioperative physician. J Cardiothorac Vasc Anesth 30 (2016), 823–830.
14. Ghadimi, K., Dombrowski, K.E., Levy, J.H., et al. Andexanet alfa for the reversal of factor Xa inhibitor related anticoagulation. Expert Rev Hematol 9 (2016), 115–122.
15. Connolly, S.J., Milling, T.J. Jr, Eikelboom, J.W., et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 375 (2016), 1131–1141.
16. Pollack, C.V. Jr, Reilly, P.A., Eikelboom, J., et al. Idarucizumab for dabigatran reversal. N Engl J Med 373 (2015), 511–520.
17. Levi, M., Moore, K.T., Castillejos, C.F., et al. Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost 12 (2014), 1428–1436.
18. Tripodi, A., Padovan, L., Veena, C., et al. How the direct oral anticoagulant apixaban affects thrombin generation parameters. Thromb Res 135 (2015), 1186–1190.
19. Rathbun, S., Tafur, A., Grant, R., et al. Comparison of methods to determine rivaroxaban anti-factor Xa activity. Thromb Res 135 (2015), 394–397.
20. Gessoni, G., Valverde, S., Valle, L., et al. Effect of dabigatran on a prothrombinase-based assay for detecting activated protein C resistance: An ex vivo and in vitro study in normal subjects and factor V Leiden carriers. Blood Transfus 7 (2017), 1–6.
21. Andersen, N.D., Bhattacharya, S.D., Williams, J.B., et al. Intraoperative use of low-dose recombinant activated factor VII during thoracic aortic operations. Ann Thorac Surg 93 (2012), 1921–1928 discussion 8–9.
22. O'Connell, K.A., Wood, J.J., Wise, R.P., et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 295 (2006), 293–298.
23. Levi, M., Levy, J.H., Andersen, H.F., et al. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 363 (2010), 1791–1800.
24. Jooste, E.H., Machovec, K.A., Einhorn, L.M., et al. 3-factor prothrombin complex concentrates in infants with refractory bleeding after cardiac surgery. J Cardiothorac Vasc Anesth 30 (2016), 1627–1631.
25. Levy, J.H., Welsby, I., Goodnough, L.T., Fibrinogen as a therapeutic target for bleeding: A review of critical levels and replacement therapy. Transfusion 54 (2014), 1389–1405 quiz 8.
26. Levy, J.H., Goodnough, L.T., How I use fibrinogen replacement therapy in acquired bleeding. Blood 125 (2015), 1387–1393.
27. Blome, M., Isgro, F., Kiessling, A.H., et al. Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery. Thromb Haemost 93 (2005), 1101–1107.
28. Charbit, B., Mandelbrot, L., Samain, E., et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost 5 (2007), 266–273.
29. Practice guidelines for blood component therapy: A report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology 84 (1996), 732–747.
30. Pereira, A., Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: Risk comparison in the case of an emerging transfusion-transmitted infection. Haematologica 92 (2007), 846–849.
31. Backholer, L., Wiltshire, M., Proffitt, S., et al. Paired comparison of methylene blue- and amotosalen-treated plasma and cryoprecipitate. Vox Sang 110 (2016), 352–361.
32. Rahe-Meyer, N., Pichlmaier, M., Haverich, A., et al. Bleeding management with fibrinogen concentrate targeting a high-normal plasma fibrinogen level: A pilot study. Br J Anaesth 102 (2009), 785–792.
33. Solomon, C., Pichlmaier, U., Schoechl, H., et al. Recovery of fibrinogen after administration of fibrinogen concentrate to patients with severe bleeding after cardiopulmonary bypass surgery. Br J Anaesth 104 (2010), 555–562.
34. Rahe-Meyer, N., Solomon, C., Hanke, A., et al. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: A randomized, placebo-controlled trial. Anesthesiology 118 (2013), 40–50.
35. Ranucci, M., Baryshnikova, E., Crapelli, G.B., et al. Randomized, double-blinded, placebo-controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. J Am Heart Assoc, 4, 2015, e002066.
36. Bilecen, S., de Groot, J.A., Kalkman, C.J., et al. Effect of fibrinogen concentrate on intraoperative blood loss among patients with intraoperative bleeding during high-risk cardiac surgery: A randomized clinical trial. JAMA 317 (2017), 738–747.
37. Rahe-Meyer, N., Levy, J.H., Mazer, C.D., et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): A double-blind phase III study of haemostatic therapy. Br J Anaesth 117 (2016), 41–51.
38. Solomon, C., Hagl, C., Rahe-Meyer, N., Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. Br J Anaesth 110 (2013), 947–956.
39. Gorlinger, K., Dirkmann, D., Hanke, A.A., et al. First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: A retrospective, single-center cohort study. Anesthesiology 115 (2011), 1179–1191.
40. Bolliger, D., Gorlinger, K., Tanaka, K.A., Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution. Anesthesiology 113 (2010), 1205–1219.
41. Weber, C.F., Gorlinger, K., Meininger, D., et al. Point-of-care testing: A prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology 117 (2012), 531–547.